THE JOURNAL OF ANTIBIOTICS

ARUGOMYCIN, A NEW ANTHRACYCLINE ANTIBIOTIC

I. TAXONOMY, FERMENTATION, ISOLATION AND PHYSICO-CHEMICAL PROPERTIES

HIROYUKI KAWAI, YOICHI HAYAKAWA, MASAYA NAKAGAWA, KAZUO FURIHATA, KEIKO FURIHATA, AKIRA SHIMAZU, HARUO SETO* and NOBORU ŌTAKE

Institute of Applied Microbiology, The University of Tokyo, Bunkyo-ku, Tokyo 113, Japan

(Received for publication November 17, 1986)

Arugomycin (AGM) is a new anthracycline antibiotic produced by strain No. 1098-AV₂ which was identified as *Streptomyces violaceochromogenes*. AGM was isolated by solvent extraction, silicic acid chromatography and Sephadex LH-20 column chromatography. Acid treatment of AGM gave the chromophore, named arugorol, which was identified as 4'-epi-nogalarol, and sugar moieties. AGM inhibited the growth of Gram-positive bacteria and showed antitumor activity against sarcoma S-180 and Ehrlich ascites tumors.

During the course of our screening program for new antitumor antibiotics, the cultured broth of a strain No. 1098-AV₂, which was isolated from a soil sample collected at Motoyama, Saga, Japan, was found to induce the differentiation of M1 cells and to show antimicrobial activities against Grampositive bacteria. The organism produced a new anthracycline antibiotic named arugomycin (AGM)¹⁾. This paper describes the taxonomy of the producing organism, and the production, isolation and physico-chemical properties of AGM.

Taxonomy

Taxonomic studies were carried out following the procedures of the International Streptomyces $Project^{2}$.

Morphological Characteristics

The aerial mycelium branched monopodially. Sporophores formed spore chains with 10 to 25 spores per chain. The morphology of spore chains was terminal compact spiral $(2 \sim 3 \ \mu m$ in diameter, $1 \sim 4 \ turns$). The spores were cylindrical or ellipsoidal $(0.7 \sim 0.9 \times 0.5 \sim 0.6 \ \mu m)$ with smooth surface. On nutrient agar medium, spores were also formed on substrate mycelium singly or in short chain $(2 \sim 15 \ spores \ per \ chain)$ which curved irregularly. The other special morphology were not observed. Whole cell hydrolysate of the strain 1098-AV₂ contained L₁L-diaminopimelic acid which suggests that the strain belongs to cell wall type I.

Cultural and Physiological Characteristics

The cultural and physiological characteristics are shown in Tables 1 and 2, respectively. The description in Table 1 follows the color standard "Color Harmony Manual" published by Container Corporation of America, U.S.A.

The Properties of Strain 1098-AV₂

The properties of strain 1098-AV₂ such as the presence of L_{L} -diaminopimelic acid in the cell wall

| Glycerol - asparagine agar | AM: | Grey |
|-----------------------------------|-------------|------------------------------------|
| | RC : | Pale orange to light yellow orange |
| | SP : | Pale orange to brownish white |
| Inorganic salts - starch agar | AM : | Grey to red |
| | RC : | Pale yellow orange |
| | SP : | None |
| Yeast extract - malt extract agar | AM: | Grey |
| | RC : | Light yellow to orange dark orange |
| | SP : | Pale brown to light orange |
| Oatmeal agar | AM : | Grey to red |
| | RC : | Pale orange to light yellow orange |
| | SP : | Pale orange to light yellow orange |

Table 1. Cultural characteristics of Streptomyces violaceochromogenes 1098-AV₂.

AM: Aerial mass color, RC: reverse color of colony, SP: soluble pigments.

and of the spore chains with more than 10 spores suggested that the strain 1098-AV₂ belongs to the genus *Streptomyces*. The following characteristics of the strain 1098-AV₂ were almost the same as those of *Streptomyces violaceochromogenes*³⁾.

a) Spore chain was terminal compact spiral.
b) Spore surface was smooth.
c) Color of colony was grey or red color-series.
d) Reverse side of colony had no distinctive pigments (pale orange, bright yellow or dark orange).
e) Melanoid pigments were produced.

Although the carbon utilization of the strain 1098-AV₂ was slightly different from that of *S. violaceochromogenes* (with regard to L-rhamnose and raffinose), the strain 1098-AV₂ was identified as a new strain of *S. violaceochromogenes*.

Fermentation

Table 2. Physiological characteristics of *Strepto*myces violaceochromogenes 1098-AV₂.

| · · · · · · · · · · · · · · · · · · · | |
|---------------------------------------|----------|
| Temperature range for growth | 20~40°C |
| Optimum growth temperature | 27∼37°C |
| Liquefaction of gelatin | + |
| Hydrolysis of starch | + |
| Coagulation of milk | _ |
| Peptonization of milk | + |
| Production of melanoid pigments: | |
| Tyrosine agar | + |
| Peptone - yeast - iron agar | + |
| Tryptone - yeast broth | + |
| Carbon utilization: | |
| L-Arabinose | + |
| D-Xylose | +- |
| D-Glucose | + |
| D-Fructose | + |
| Sucrose | +- |
| Inositol | + |
| L-Rhamnose | |
| Raffinose | <u>+</u> |
| D-Mannitol | + |
| | |

+: Positive, \pm : doubtful, -: negative.

Growth from a well-grown agar slant of S.

violaceochromogenes 1098-AV₂ was used to inoculate the seed medium shown in Table 3. This was incubated at 27°C for 72 hours on a rotary shaker (200 rpm). The vegetative culture was inoculated to a 50-liter jar fermentors containing 25 liters of the production medium. Culture conditions are shown in Table 3. The cultured broth exhibited the maximum accumulation of AGM after 96 hours of fermentation. A typical time course of fermentation is shown in Fig. 1.


Purification of AGM

AGM was purified to microcrystalline powder by the procedures illustrated in Fig. 2. The cultured broth filtrate (25 liters) was adjusted to pH 2.0 and applied to a Diaion HP-20 column. AGM was eluted with methanol after washing the column with water. The eluate was concentrated to a small volume *in vacuo* followed by extraction with chloroform. The solvent layer was evaporated to give crude AGM which was further purified by chromatography on a silicic gel column with chloro-

| Seed culture | | | |
|--------------------|--------------|-----------------------------|------|
| Medium: | | | |
| pH | | 7.3 | |
| Glucose (%) | | 0.4 | |
| Malt extract (% |) | 1.0 | |
| Yeast extract (% | 9 | 0.4 | |
| Vitamin complex | x* (ml/liter | r) 10 | |
| *Vitamin complex | (mg/10 m) | b) | |
| Thiamine - HCl | 0.5 | Ca-pantothenate | 0.5 |
| Riboflavin | 0.5 | <i>p</i> -Aminobenzoic acid | 0.5 |
| Niacin | 0.5 | Biotin | 0.25 |
| Pyridoxine - HCl | 0.5 | Inositol | 0.5 |
| Condition: | 27°C, | 72 hours, 200 rpm | |
| Production culture | | | |
| Medium: | | | |
| pH | | 7.0 | |
| Starch (%) | | 2.5 | |
| Soybean meal (? | 2 | 1.5 | |
| Dry yeast (%) | • | 0.2 | |
| $CaCO_3$ (%) | | 0.4 | |
| Condition: | 27°C, | 96 hours, 200 rpm | |

Table 3. Culture conditions for production of arugomycin.

Fig. 1. Fermentation process of arugomycin by *Streptomyces violaceochromogenes* 1098-AV₂. PV: Packed volume 3,000 rpm×10 minutes. OD: Optical density at 476 nm. Antimicrobial activity: Activity against *Bacillus subtilis* indicated in diameter.




form - methanol (20:1). The active fraction was applied to a Sephadex LH-20 column and developed with chloroform - methanol (1:1). The eluate was concentrated *in vacuo* to give an orange powder (2.5 g) of pure AGM.

Physico-chemical Properties

Physico-chemical properties of AGM are summarized in Table 4. The UV and visible spectra showed absorption maxima in a methanol solution at 235, 258, 292 and 476 nm, the last one shifted to 550 nm in an alkaline solution. The UV and visible spectra are similar to those of nogalarol.

The IR spectrum (KBr) of AGM indicated the presence of hydroxyl (3430 cm^{-1}), hydroxyanthraquinone ($1660 \text{ and } 1640 \text{ cm}^{-1}$) and ester carbonyl (1740 cm^{-1}) moieties.






Table 4. Physico-chemical properties of arugomycin.


| Appearance | Orange powder |
|--|---|
| Molecular formula | $C_{30}H_{112}O_{37}N_2$ |
| MW (SI-MS) | <i>m</i> / <i>z</i> 1,694 (MH) ⁺ |
| Elemental analysis | |
| Found: | C 56.22, H 6.85, N 1.78, O 35.14. |
| Calcd for: | C 56.71, H 6.67, N 1.65, O 34.97. |
| MP (°C) | 208~212 |
| $[lpha]_{ m D}^{25}$ | $+112^{\circ}$ (c 0.1, CHCl ₃ - CH ₃ OH, 9:1) |
| UV λ_{\max} nm (E ^{1%} _{lcm}) | |
| MeOH | 235 (363), 258 (167), 292 (61), 476 (104) |
| MeOH+0.1 N HCl | 235 (387), 258 (159), 292 (61), 468 (110) |
| MeOH+0.1 N NaOH | 239 (302), 294 (41), 543 (88) |
| IR ν_{max} (KBr) cm ⁻¹ | 3430, 1740, 1660, 1640 |
| | |


SI-MS: Secondary ion mass spectrum.

The ¹H NMR spectrum shown in Fig. 3 (400 MHz, in pyridine- d_5) indicated the presence of one carbomethoxy group ($\delta_{\rm H}$ 3.6), four methoxy groups ($\delta_{\rm H}$ 3.2~3.4), and one dimethyl amino group ($\delta_{\rm H}$ 2.7).


Treatment of AGM (200 mg) with 40% formic acid (40 minutes, 85° C) gave a mixture of the aglycone and sugar moieties. The aglycone was separated from the sugar moieties by adsorbing on a Diaion HP-20 column. It was further purified by preparative silica gel TLC and Sephadex LH-20 column chromatography to give 42 mg of arugorol (AGR).


The physico-chemical properties of AGR are summarized in Table 5.





The ¹³C NMR spectrum of AGR (Table 6) is very similar to that of nogalarol⁴) (NOG) except for the signals due to the amino sugar moiety directly fused to the aglycone [C-2' to C-6' and N(CH₃)₂]. The large upfield shift of C-2' (δ_{c} 73.5 in NOG to δ_{c} 67.4 in AGR) is clearly ascribed to the stereochemical change of C-4' (γ effect)⁵⁾. In agreement with this, the ¹H NMR coupling constants of AGR indicated that the amino sugar moiety was 3,6-dideoxy-3-dimethylaminogalactopyranose with axial configurations for 2'-H ($J_{1',2'}$ =3.0 Hz and $J_{2',3'}$ =11.0 Hz) and 3'-H $(J_{2',3'}=11.0 \text{ Hz and } J_{3',4'}=2.6 \text{ Hz})$, and an equatorial configuration for 4'-H ($J_{3',4'}$ = 2.6 Hz). On the other hand, the ¹H NMR coupling constants of NOG were reported to be as follows; for 2'-H $(J_{1',2'}=3.3 \text{ Hz} \text{ and } J_{2',3'}=$








Table 6. ¹³C NMR chemical shifts of arugorol (AGR), the aglycone part of arugomycin (AGM) and nogalarol (NOG).

| Carbon | AGR in CD ₃ OD | AGM in pyridine- d_5 | NOG ⁴⁾ in DMF- d_7 |
|---------|---------------------------|------------------------|---------------------------------|
| 1 | 147.5 | 147.9 | 148.0 |
| 2 | 138.6 | 140.1 | 138.1 |
| 3 | 123.8 | 122.3 | 125.2 |
| 4 | 157.0 | 156.5 | 155.7 |
| 4a | 115.7 | 115.3 | 115.4 |
| 5 | 191.1 | 191.8 | 192.3 |
| 5a | 114.5 | 114.8 | 114.6 |
| 6 | 161.4 | 162.2 | 161.6 |
| 6a | 133.4 | 131.2 | 131.3 |
| 7 | 63.8 | 70.6 | 63.0 |
| 8 | 40.9 | 39.9 | 40.9 |
| 9 | 70.5 | 69.3 | 69.7 |
| 10 | 59.0 | 59.0 | 56.9 |
| 10a | 143.8 | 144.4 | 144.0 |
| 11 | 120.3 | 119.8 | 119.8 |
| 11a | 133.9 | 131.2 | 134.1 |
| 12 | 180.1 | 180.3 | 179.8 |
| 12a | 117.8 | 117.8 | 117.2 |
| 13 | 30.1 | 30.0 | 29.7 |
| 1′ | 97.5 | 97.9 | 97.8 |
| 2' | 67.4 | 67.4 | 73.5 |
| 3' | 64.7 | 62.5 | 66.8 |
| 4′ | 73.2 | 81.6 | 70.8 |
| 5' | 77.5 | 77.6 | 76.0 |
| 6′ | 22.6 | 23.6 | 24.2 |
| NCH_3 | 43.1 | 44.3 | 41.4 |
| COO | 172.3 | 171.9 | 171.9 |
| OCH_3 | 52.9 | 52.0 | 52.4 |

Table 7. Antimicrobial activity of arugomycin.

| Organisms | MIC (µg/ml) |
|--------------------------------------|----------------|
| Bacillus subtilis PCI 219P | 12.5 |
| Staphylococcus aureus FDA 209P | 12.5 |
| Micrococcus luteus ATCC 9341 | 12.5 |
| Pseudomonas aeruginosa NCTC 10490 | >100 |
| Salmonella typhimurium IFO 12529 | >100 |
| Escherichia coli NIHJ JC-2 | >100 |
| Saccharomyces cerevisiae No. Yu 1200 | >100 |
| Candida albicans IFO 0396 | >100 |
| Aspergillus fumigatus IFO 4400 | >100 |
| Penicillium chrysogenum ATCC 10002 | >100 |

Table 8. Antitumor activity of arugomycin against sarcoma S-180 ascites and Ehrlich ascites tumors.

| Dose (mg/kg) | Sarco | Ehrlich ascites ^b | |
|-----------------|------------|------------------------------|------------|
| | T/C (%) | Survivors on day 60 | T/C (%) |
| 0.063 | 93 | 0/8 | 96 |
| 0.13 | 126 | 0/8 | 107 |
| 0.25 | 199 | 0/8 | 154 |
| 0.50 | >457 | 2/8 | 189 |
| 1.0 | >464 | 3/8 | 119 |
| 2.0 | 79 | 0/8 | |

^a Treatment: 1, 5 days, ip; tumor inoculum, 1.0×10^{6} ascites cells implanted ip; host, ICR female mice.

^b Treatment: 1, 3, 5 days ip; tumor inoculum, $1.0 \times 10^{\circ}$ ascites cells implanted ip; host, *ddY* female mice.

The ¹³C NMR chemical shifts are indicated in ppm from internal TMS.

10.5 Hz), 3'-H $(J_{2',3'}=10.5$ Hz and $J_{3',4'}=10.5$ Hz) and 4'-H $(J_{3',4'}=10.5$ Hz)⁴⁾. Thus AGR is the 4'-epimer of NOG, the chromophore of nogalamycin⁴⁾, as shown in Fig. 4 with uncertainty about the absolute configuration. Comparison of the ¹³C NMR of AGM and AGR revealed the glycosidation shift of C-7 from δ_{c} 63.8 to 70.6 and C-4' from δ_{c} 73.2 to 81.6. These results suggested the attachment of sugar chains to C-7 and C-4' of the chromophore of AGM.

Biological Activities

The antimicrobial activity of AGM is summarized in Table 7. It inhibited the growth of Grampositive bacteria. LD_{50} of AGM in mice was 1.75 mg/kg by intraperitoneal injection. The activities against sarcoma S-180 and Ehrlich carcinoma are shown in Table 8.

Further structural studies of AGM will be reported in the accompanying paper.

References

¹⁾ KAWAI, H.; Y. HAYAKAWA, M. NAKAGAWA, K. IMAMURA, K. TANABE, A. SHIMAZU, H. SETO & N. ÖTAKE: Arugomycin, a new anthracycline antibiotic. J. Antibiotics 36: 1569~1571, 1983

- 2) SHIRLING, E. B. & D. GOTTLIEB: Methods for characterization of *Streptomyces* species. Int. J. Syst. Bacteriol. 16: 313~340, 1966
- 3) SHIRLING, E. B. & D. GOTTLIEB: Cooperative description of type culture of *Streptomyces*. IV. Species descriptions from the second, third and fourth studies. Int. J. Syst. Bacteriol. 19: 391 ~ 512, 1969
- 4) WILEY, P. F.; R. B. KELLY, E. L. CARON, V. H. WILEY, J. H. JOHNSON, F. A. MACKELLAR & S. A. MIZSAK: Structure of nogalamycin. J. Am. Chem. Soc. 99: 542~549, 1977
- DALLING, D. K. & D. M. GRANT: Carbon-13 magnetic resonance. IX. The methylcyclohexane. J. Am. Chem. Soc. 89: 6612~6622, 1967